Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig + R-CHOP in previously untreated large B-cell lymphoma
NCT07911553Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2026
- Primary completion
- Sep 2030
01
Overview
A Phase 3 trial of surovatamig in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
surovatamig
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07911553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911553.